Answers are grounded in this paper and cite their sources.
Background: Diabetic cataract is largely mediated by oxidative stress, inflammation, apoptosis, and increased protein glycation. Diacerein (DRN) has antioxidant and antiapoptotic effects. Aim: To investigate the possible protective effect of DRN against diabetic cataract in rats. Methods: Following the induction of diabetes by a single streptozotocin injection (45 mg/kg, i.p.), rats received DRN (50 mg/kg/day, p.o.) for 10 weeks. Results: Streptozotocin significantly increased fasting blood sugar (FBS) and lenticular malondialdehyde, nitric oxide, interleukin-1β, tumour necrosis factor-α, nuclear factor-κB p65, the Bax/Bcl-2 ratio, and cleaved caspase-3, while significantly reducing serum insulin and lenticular total antioxidant capacity. In addition, the lenses of diabetic rats showed significant increases in aldose reductase activity, sorbitol concentration, and glycated proteins, and a significant decrease in soluble proteins. DRN significantly reduced FBS, malondialdehyde, nitric oxide, interleukin-1β, tumour necrosis factor-α, nuclear factor-κB p65, the Bax/Bcl-2 ratio, and cleaved caspase-3, while significantly increasing serum insulin and total antioxidant capacity. DRN also significantly decreased aldose reductase activity, sorbitol concentration, and glycated proteins, and significantly increased soluble proteins in the lenses of diabetic rats. Conclusion: DRN significantly protected against diabetic cataract through its antioxidant, anti-inflammatory, antiapoptotic, and antidiabetic properties.
No takes yet. Share an insight, caveat, or question.
Al-Ghamdi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: